Trials / Completed
CompletedNCT01932385
Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma
Phase 2 Study of Sorafenib in the Management of Liver Function Impaired Advanced Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Qingdao Central Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Due to the HBV and HCV infection, about 55% hepatocellular carcinoma patients happened in China. Among them, only 10% patients can be diagnosed in early stage. Sorafenib increased PFS and OS in advanced hepatocellular carcinoma patients with liver function of Child-Pugh class A patients, but the result for Child-Pugh class B patients is unclear.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib | |
| OTHER | Best Supportive Care |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2016-01-30
- Completion
- 2016-07-30
- First posted
- 2013-08-30
- Last updated
- 2018-02-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01932385. Inclusion in this directory is not an endorsement.